2M7C Stock Overview An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
China Medical System Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for China Medical System Holdings Historical stock prices Current Share Price HK$0.85 52 Week High HK$1.46 52 Week Low HK$0.71 Beta 0.93 1 Month Change -5.52% 3 Month Change -3.93% 1 Year Change -31.60% 3 Year Change -38.93% 5 Year Change -27.54% Change since IPO 201.34%
Recent News & Updates
China Medical System Holdings Limited Obtains Class 1 Innovative Drug Long-Acting Anti-Il-4Ra Monoclonal Antibody Mg-K10 Jan 25
China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China Dec 09
China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug Nov 27
China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong Nov 05
Insufficient new directors Nov 01
Investor sentiment improves as stock rises 15% Sep 30 See more updates
China Medical System Holdings Limited Obtains Class 1 Innovative Drug Long-Acting Anti-Il-4Ra Monoclonal Antibody Mg-K10 Jan 25
China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China Dec 09
China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug Nov 27
China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong Nov 05
Insufficient new directors Nov 01
Investor sentiment improves as stock rises 15% Sep 30
China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China Sep 24
Founder recently bought €415k worth of stock Aug 28
First half dividend of HK$0.16 announced Aug 19
First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023) Aug 18
New minor risk - Profit margin trend Aug 16
China Medical System Holdings Limited Announces Re-Designation of Directors Aug 16 China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024
China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China Aug 06
China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024 Aug 05
Now 25% undervalued after recent price drop Jul 01
China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China Jun 25
Founder recently bought €866k worth of stock Jun 19
Now 20% undervalued after recent price drop Jun 19
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection Jun 18
Now 20% undervalued after recent price drop Jun 12
Founder recently bought €802k worth of stock May 26
Now 20% undervalued after recent price drop May 21
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023 May 10
Upcoming dividend of HK$0.086 per share May 08
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China Apr 23
Now 21% undervalued after recent price drop Apr 15
Final dividend of HK$0.086 announced Apr 01
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024 Mar 30
New major risk - Share price stability Mar 29
Now 38% undervalued after recent price drop Mar 29
China Medical System Holdings Limited, Annual General Meeting, May 09, 2024 Mar 28
Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022) Mar 28
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024 Mar 27
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China Mar 20
China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China Dec 12
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China Dec 04
Upcoming dividend of HK$0.34 per share at 5.1% yield Sep 04
First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022) Aug 30
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023 Aug 29
China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023 Aug 18
New minor risk - Share price stability Aug 14
China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray Jun 13
National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI May 31
Upcoming dividend of HK$0.27 per share at 4.7% yield Apr 26
Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021) Apr 06
Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021) Mar 17
China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Feb 16
China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China Dec 20
Investor sentiment improved over the past week Dec 02
Upcoming dividend of HK$0.34 per share Aug 29
First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021) Aug 24
China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022 Aug 23
China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022 Aug 11
China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021 Apr 23
Upcoming dividend of HK$0.28 per share Apr 19
Investor sentiment improved over the past week Mar 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022 Mar 06
China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China Dec 10
Independent Non-Executive Director Chi Keung Wu has left the company Oct 12
China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria Sep 29
Upcoming dividend of HK$0.32 per share Aug 30
First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020) Aug 25
National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe Aug 14
China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Aug 04
Investor sentiment deteriorated over the past week Jul 27
China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China Jul 23
Investor sentiment deteriorated over the past week Jul 08
China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China Jul 06
China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020 Apr 29
Upcoming dividend of HK$0.24 per share Apr 23
Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019) Apr 04
Full year 2020 earnings released Mar 17 China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021
New 90-day high: €1.53 Mar 13
Investor sentiment improved over the past week Mar 13
China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021 Mar 05
Investor sentiment deteriorated over the past week Feb 25
Investor sentiment improved over the past week Feb 04
China Medical System Holdings Limited (SEHK:867) acquired Luqa Ventures Co., Ltd. from third party sellers. Feb 02
New 90-day high: €1.11 Jan 22
Investor sentiment improved over the past week Jan 21
China Medical System Holdings Limited Announces Desidustat Tablets Being Granted an Approval for Drug Clinical Trial Jan 20
Investor sentiment improved over the past week Jan 09
New 90-day high: €0.98 Jan 07
Founder recently bought €2.4m worth of stock Dec 17
New 90-day low: €0.76 Dec 16
China Medical System Holdings Limited through its Wholly-Owned Subsidiary Signs License, Collaboration and Distribution Agreement with Cosmo Technologies Ltd Dec 06
New 90-day low: €0.85 Nov 26
New 90-day low: €0.91 Oct 24
New 90-day low: €0.92 Sep 29
China Medical System Holdings Limited Signs A Distribution, Supply and License Agreement (The "License Agreement"), with medac Gesellschaft für klinische Spezialpräparate mbH Sep 22
Founder recently bought €1.9m worth of stock Sep 05
New 90-day low - €0.93 Aug 29
First half earnings released Aug 29 Shareholder Returns 2M7C DE Pharmaceuticals DE Market 7D 0% 1.5% 1.9% 1Y -31.6% -7.6% 15.1%
See full shareholder returns
Return vs Market: 2M7C underperformed the German Market which returned 15.2% over the past year.
Price Volatility Is 2M7C's price volatile compared to industry and market? 2M7C volatility 2M7C Average Weekly Movement 3.7% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2M7C has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2M7C's weekly volatility (4%) has been stable over the past year.
About the Company China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
Show more China Medical System Holdings Limited Fundamentals Summary How do China Medical System Holdings's earnings and revenue compare to its market cap? 2M7C fundamental statistics Market cap €2.10b Earnings (TTM ) €184.98m Revenue (TTM ) €933.24m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2M7C income statement (TTM ) Revenue CN¥7.01b Cost of Revenue CN¥1.85b Gross Profit CN¥5.17b Other Expenses CN¥3.78b Earnings CN¥1.39b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.58 Gross Margin 73.66% Net Profit Margin 19.82% Debt/Equity Ratio 6.9%
How did 2M7C perform over the long term?
See historical performance and comparison Dividends
6.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 15:46 End of Day Share Price 2025/01/31 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources China Medical System Holdings Limited is covered by 33 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jessica Li BofA Global Research Lok Kwan Chiu CCB International Securities Limited Harry He China Galaxy International Securities (Hong Kong)
Show 30 more analysts 
